Ensysce Biosciences Inc.

Ensysce Biosciences Inc.

The company was founded in the early 2000s but no founding principals are publicly named. Ensysce operates as a publicly traded entity — shares listed on NASDAQ under ticker ENSC — and its primary focus is developing a pipeline of abuse-deterrent opioid candidates. Strategy centers on two platforms: TAAP, which releases an opioid only after being activated by trypsin in the gastrointestinal tract; and PF614, a prodrug that resists crushing or injecting. The lead product, PF614-MPAR, targets moderate-to-severe pain. Ensysce has no disclosed asset-class mix or fund structure; it relies on equity raises and partnerships for capital. As of 2024, Ensysce's team size has not been publicly disclosed. The company's offices are at 7946 Ivanhoe Avenue, Suite 201 in La Jolla, with no additional known locations. No adjacent vehicles like investing arms or foundations have been reported. A structural differentiator is Ensysce's use of trypsin-activated chemistry, which attempts to block opioid misuse via biochemical gating rather than physical barriers. This approach distinguishes its products from earlier abuse-deterrent formulations approved by the FDA.